NextDecade Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NextDecade Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | $0 | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 25, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Mar 6, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 8, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($429.64M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $277.45M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($221.64M) | Mar 2, 2026 |
| FY2022 | Dec 31, 2022 | ($60.07M) | Mar 10, 2023 |
| FY2022 | Dec 31, 2021 | ($22.04M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($14.33M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($35.87M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($41.96M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($35.33M) | Mar 6, 2019 |
| FY2016 | Dec 31, 2016 | ($434.7K) | Mar 10, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($225.93M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($171.08M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($122.67M) | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | ($54.48M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($19.51M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($22.01M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($35.00M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($43.02M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($35.64M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($8.50M) | Mar 8, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.01M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $8.26M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $4.89M | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | $4.10M | Mar 11, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($169.40M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($95.59M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($73.62M) | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | ($40.08M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($17.96M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($26.25M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($40.70M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($23.29M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($12.83M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($7.19M) | Mar 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.85B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $2.57B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.74B | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | $33.75M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $12.11M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $32.35M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $20.30M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $18.66M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $14.83M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $19.39M | Mar 8, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.43B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $6.40B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $3.32B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $312.43M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $222.11M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $201.67M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $221.20M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $169.00M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $116.09M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $75.78M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.12B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $4.66B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $2.58B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $55.62M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $33.81M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $28.93M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $33.58M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $19.53M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $13.00M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $7.68M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $377.64M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $287.92M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $54.37M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $19.89M | Mar 10, 2023 |
| FY2022 | Dec 31, 2020 | $60.43M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $89.72M | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $83.22M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $103.09M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $68.10M | Mar 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($759.96M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($453.52M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($391.77M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($230.14M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($170.07M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($148.03M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($133.70M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($97.62M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($55.62M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($20.29M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $143.78M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $148.14M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $38.24M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $62.79M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $25.55M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $22.61M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $15.74M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.17M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $35.70M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $12.52M | Mar 8, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.83B | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $4.04B | Feb 28, 2025 |
| FY2023 | Dec 31, 2023 | $1.82B | Mar 11, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Mar 11, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 260.20M | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | 256.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 143.50M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 120.80M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 117.80M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 117.30M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 106.90M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 106.30M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 95.70M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | 4.50M | Mar 10, 2017 |